2zjc › Citations

Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.

Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y
J Mol Biol 385 1221-9 (2009)
Cited: 48 times
EuropePMC logo PMID: 19084540

Abstract

Tumor necrosis factor (TNF) is an important cytokine that suppresses carcinogenesis and excludes infectious pathogens to maintain homeostasis. TNF activates its two receptors [TNF receptor (TNFR) 1 and TNFR2], but the contribution of each receptor to various host defense functions and immunologic surveillance is not yet clear. Here, we used phage display techniques to generate receptor-selective TNF mutants that activate only one TNFR. These TNF mutants will be useful in the functional analysis of TNFR. Six amino acids in the receptor binding interface (near TNF residues 30, 80, and 140) were randomly mutated by polymerase chain reaction. Two phage libraries comprising over 5 million TNF mutants were constructed. By selecting the mutants without affinity for TNFR1 or TNFR2, we successfully isolated 4 TNFR2-selective candidates and 16 TNFR1-selective candidates, respectively. The TNFR1-selective candidates were highly mutated near residue 30, whereas TNFR2-selective candidates were highly mutated near residue 140, although both had conserved sequences near residues 140 and 30, respectively. This finding suggested that the phage display technique was suitable for identifying important regions for the TNF interaction with TNFR1 and TNFR2. Purified clone R1-6, a TNFR1-selective candidate, remained fully bioactive and had full affinity for TNFR1 without activating TNFR2, indicating the usefulness of the R1-6 TNF mutant in analyzing TNFR1 receptor function. To further elucidate the receptor selectivity of R1-6, we examined the structure of R1-6 by X-ray crystallography. The results suggested that R31A and R32G mutations strongly influenced electrostatic interaction with TNFR2, and that L29K mutation contributed to the binding of R1-6 to TNFR1. This phage display technique can be used to efficiently construct functional mutants for analysis of the TNF structure-function relationship, which might facilitate in silico drug design based on receptor selectivity.

Articles - 2zjc mentioned but not cited (6)

  1. In Silico Prediction of Molecular Targets of Astragaloside IV for Alleviation of COVID-19 Hyperinflammation by Systems Network Pharmacology and Bioinformatic Gene Expression Analysis. Ge C, He Y. Front Pharmacol 11 556984 (2020)
  2. Screening of the Hepatotoxic Components in Fructus Gardeniae and Their Effects on Rat Liver BRL-3A Cells. Li C, Lan M, Lv J, Zhang Y, Gao X, Gao X, Dong L, Luo G, Zhang H, Sun J. Molecules 24 E3920 (2019)
  3. Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex. Mukai Y, Nakamura T, Yoshioka Y, Tsunoda S, Kamada H, Nakagawa S, Yamagata Y, Tsutsumi Y. Acta Crystallogr Sect F Struct Biol Cryst Commun 65 295-298 (2009)
  4. Effect of naringenin and its combination with cisplatin in cell death, proliferation and invasion of cervical cancer spheroids. Martínez-Rodríguez OP, González-Torres A, Álvarez-Salas LM, Hernández-Sánchez H, García-Pérez BE, Thompson-Bonilla MDR, Jaramillo-Flores ME. RSC Adv 11 129-141 (2020)
  5. Utilizing network pharmacology and molecular docking to explore the underlying mechanism of Guizhi Fuling Wan in treating endometriosis. Wang H, Zhou G, Zhuang M, Wang W, Fu X. PeerJ 9 e11087 (2021)
  6. [Exploring the therapeutic mechanism of Simiao pills for hyperuricemia based on network pharmacology and molecular docking]. Zeng L, Deng Y, Chen J, Sun X, Liu Y, Nie X, Zhou L, Zhao X, Dai J. Nan Fang Yi Ke Da Xue Xue Bao 41 579-587 (2021)


Reviews citing this publication (14)

  1. TNF receptor 2 pathway: drug target for autoimmune diseases. Faustman D, Davis M. Nat Rev Drug Discov 9 482-493 (2010)
  2. Cytokines and epilepsy. Li G, Bauer S, Nowak M, Norwood B, Tackenberg B, Rosenow F, Knake S, Oertel WH, Hamer HM. Seizure 20 249-256 (2011)
  3. Regulation of TNF-α with a focus on rheumatoid arthritis. Moelants EA, Mortier A, Van Damme J, Proost P. Immunol Cell Biol 91 393-401 (2013)
  4. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM. Clin Rev Allergy Immunol 53 40-53 (2017)
  5. Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. Fischer R, Kontermann RE, Pfizenmaier K. Front Cell Dev Biol 8 401 (2020)
  6. Engineering signal transduction pathways. Kiel C, Yus E, Serrano L. Cell 140 33-47 (2010)
  7. Insights into the biology and therapeutic implications of TNF and regulatory T cells. Salomon BL. Nat Rev Rheumatol 17 487-504 (2021)
  8. Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. Stübgen JP. J Neurol 258 961-970 (2011)
  9. Transmembrane TNF and Its Receptors TNFR1 and TNFR2 in Mycobacterial Infections. Ruiz A, Palacios Y, Garcia I, Chavez-Galan L. Int J Mol Sci 22 5461 (2021)
  10. Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca2+ signaling. Balistrieri A, Makino A, Yuan JX. Physiol Rev 103 1827-1897 (2023)
  11. Development of novel drug delivery systems using phage display technology for clinical application of protein drugs. Nagano K, Tsutsumi Y. Proc Jpn Acad Ser B Phys Biol Sci 92 156-166 (2016)
  12. [Creation of TNFR1-selective antagonist and its therapeutic effects]. Nomura T, Abe Y, Yoshioka Y, Nakagawa S, Tsunoda S, Tsutsumi Y. Yakugaku Zasshi 130 63-68 (2010)
  13. Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative? Palacios Y, Chavez-Galan L. Pharmaceuticals (Basel) 15 616 (2022)
  14. [Development of New Biologics through Creation of a Functional Cytokine Mutant]. Kamada H. Yakugaku Zasshi 135 843-849 (2015)

Articles citing this publication (28)

  1. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, Guo Y, Lou Z. J Biol Chem 288 27059-27067 (2013)
  2. Elucidating glycosaminoglycan-protein-protein interactions using carbohydrate microarray and computational approaches. Rogers CJ, Clark PM, Tully SE, Abrol R, Garcia KC, Goddard WA, Hsieh-Wilson LC. Proc Natl Acad Sci U S A 108 9747-9752 (2011)
  3. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab. Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Hu S, Wang H, Rao Z, Guo Y, Lou Z. J Biol Chem 288 13799-13807 (2013)
  4. Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways. Xu X, Piao HN, Aosai F, Zeng XY, Cheng JH, Cui YX, Li J, Ma J, Piao HR, Jin X, Piao LX. Br J Pharmacol 177 5224-5245 (2020)
  5. Enriching the human apoptosis pathway by predicting the structures of protein-protein complexes. Acuner Ozbabacan SE, Keskin O, Nussinov R, Gursoy A. J Struct Biol 179 338-346 (2012)
  6. Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function. Warren JT, Zou W, Decker CE, Rohatgi N, Nelson CA, Fremont DH, Teitelbaum SL. J Cell Biochem 116 2476-2483 (2015)
  7. Citrullination of TNF-α by peptidylarginine deiminases reduces its capacity to stimulate the production of inflammatory chemokines. Moelants EA, Mortier A, Grauwen K, Ronsse I, Van Damme J, Proost P. Cytokine 61 161-167 (2013)
  8. Crystal structure of TNFalpha complexed with a poxvirus MHC-related TNF binding protein. Yang Z, West AP, Bjorkman PJ. Nat Struct Mol Biol 16 1189-1191 (2009)
  9. Apoptosis through Death Receptors in Temporal Lobe Epilepsy-Associated Hippocampal Sclerosis. Teocchi MA, D'Souza-Li L. Mediators Inflamm 2016 8290562 (2016)
  10. A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis. Ma Y, Zhao S, Shen S, Fang S, Ye Z, Shi Z, Hong A. Sci Rep 5 13595 (2015)
  11. Deep brain stimulation of the anterior nucleus of the thalamus reverses the gene expression of cytokines and their receptors as well as neuronal degeneration in epileptic rats. Chen YC, Zhu GY, Wang X, Shi L, Jiang Y, Zhang X, Zhang JG. Brain Res 1657 304-311 (2017)
  12. Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Reis CR, van Assen AH, Quax WJ, Cool RH. Mol Cell Proteomics 10 M110.002808 (2011)
  13. Application of fourier transform and proteochemometrics principles to protein engineering. Cadet F, Fontaine N, Vetrivel I, Ng Fuk Chong M, Savriama O, Cadet X, Charton P. BMC Bioinformatics 19 382 (2018)
  14. Delivery of a TNF-α-derived peptide by nanoparticles enhances its antitumor activity by inducing cell-cycle arrest and caspase-dependent apoptosis. Yan Q, Chen X, Gong H, Qiu P, Xiao X, Dang S, Hong A, Ma Y. FASEB J fj201800377R (2018)
  15. Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists. Mukai Y, Nakamura T, Yoshioka Y, Shibata H, Abe Y, Nomura T, Taniai M, Ohta T, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y. J Biochem 146 167-172 (2009)
  16. Structural modeling of tumor necrosis factor: A protein of immunological importance. Roy U. Biotechnol Appl Biochem 64 454-463 (2017)
  17. Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis. Wang Y, van Assen AHG, Reis CR, Setroikromo R, van Merkerk R, Boersma YL, Cool RH, Quax WJ. FEBS J 284 2501-2512 (2017)
  18. Functionality of intrinsic disorder in tumor necrosis factor-α and its receptors. Uversky VN, El-Baky NA, El-Fakharany EM, Sabry A, Mattar EH, Uversky AV, Redwan EM. FEBS J 284 3589-3618 (2017)
  19. Novel protein engineering strategy for creating highly receptor-selective mutant TNFs. Nomura T, Abe Y, Kamada H, Inoue M, Kawara T, Arita S, Furuya T, Yoshioka Y, Shibata H, Kayamuro H, Yamashita T, Nagano K, Yoshikawa T, Mukai Y, Nakagawa S, Taniai M, Ohta T, Tsunoda S, Tsutsumi Y. Biochem Biophys Res Commun 388 667-671 (2009)
  20. Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique. Ando D, Inoue M, Kamada H, Taki S, Furuya T, Abe Y, Nagano K, Tsutsumi Y, Tsunoda SI. Biochem Biophys Rep 7 309-315 (2016)
  21. NF-κB signaling and cell-fate decision induced by a fast-dissociating tumor necrosis factor mutant. Zhang X, Yin N, Guo A, Zhang Q, Zhang Y, Xu Y, Liu H, Tang B, Lai L. Biochem Biophys Res Commun 489 287-292 (2017)
  22. Breed and adaptive response modulate bovine peripheral blood cells' transcriptome. Pošćić N, Montanari T, D'Andrea M, Licastro D, Pilla F, Ajmone-Marsan P, Minuti A, Sgorlon S. J Anim Sci Biotechnol 8 11 (2017)
  23. Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2. Shibata H, Abe Y, Yoshioka Y, Nomura T, Sato M, Kayamuro H, Kawara T, Arita S, Furuya T, Nagano K, Yoshikawa T, Kamada H, Tsunoda S, Tsutsumi Y. Cytokine 50 75-83 (2010)
  24. Rational design of TNFα binding proteins based on the de novo designed protein DS119. Zhu C, Zhang C, Zhang T, Zhang X, Shen Q, Tang B, Liang H, Lai L. Protein Sci 25 2066-2075 (2016)
  25. Anti-Inflammatory Activity and Mechanism of Hydrostatin-SN1 From Hydrophis cyanocinctus in Interleukin-10 Knockout Mice. Zhang C, Guo S, Wang J, Li A, Sun K, Qiu L, Li J, Wang S, Ma X, Lu Y. Front Pharmacol 11 930 (2020)
  26. Novel mutants of human tumor necrosis factor with dominant-negative properties. Shingarova LN, Boldyreva EF, Yakimov SA, Guryanova SV, Dolgikh DA, Nedospasov SA, Kirpichnikov MP. Biochemistry (Mosc) 75 1458-1463 (2010)
  27. Novel Descriptors and Digital Signal Processing- Based Method for Protein Sequence Activity Relationship Study. Fontaine NT, Cadet XF, Vetrivel I. Int J Mol Sci 20 E5640 (2019)
  28. [Production and properties of human tumor necrosis factor peptide fragments]. Shingarova LN, Petrovskaia LE, Nekrasov AN, Kriukova EA, Boldyreva EF, Iakimov SA, Gur'ianova SV, Dolgikh DA, Kirpichnikov MP. Bioorg Khim 36 327-336 (2010)


Quick links